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(neoadjuvant chemotherapy) and test arm (neoadjuvant chemoradiotherapy) were estimated for 11 months and 16.5 months respectively. Although neoadjuvant therapy might be promising for advanced gallbladder cancer, it has not been established as standard strategy. In that situation, I recommend the protocol would be better to set randomized phase II study to evaluate R0 resection rate of both arm (selection design) before comparison to upfront surgery. Overall survival should be measured as secondary endopoint.
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GENERAL COMMENTS
Engineer et al report the study protocol for a randomized trial of neoadjuvant chemoradiation versus chemotherapy for locally advanced gallbladder cancer.
The authors should be commended for studying this important question using a randomized trial and for recording both clinical and patient-reported outcomes (such as quality of life).
Major comment: 1. The biggest question is that of feasibility of answering the question as posed. a) The authors do not provide any details regarding how many patients they see with locally advanced gallbladder cancer per year. Furthermore, it would be helpful to know what proportion of those patients would meet study enrollment criteria. b) According to clinicaltrials.gov, the trial has been ongoing since August 2016. In the protocol, the authors state that they expected enrollment to occur over the first 3 years of the trial, which will be up in just a few months. The authors allude to a slow recruitment of patients, but do not describe how many patients have been enrolled up until this point and how this affects the timeline and likelihood of completion for the trial. c) Slow recruitment is a fact of life in the world of clinical trials.
Given that, what do the authors plan to do? Do they have any criteria for declaring futility in being able to answer the question? Do they have any plans to enlist other centers to enroll patients? Do they plan to do alternative analyses such as Bayesian analyses that may more easily accommodate small sample sizes? What is their plan?
Minor comments:
2) The reporting seems reasonable, but explicitly alluding to the CONSORT criteria and checklist would be helpful.
3) The study design states that stratification will be by T stage, and it lists T1-T4 --should this really just be T3 or T4 given the inclusion criteria? 4) In adjudicating the outcome of completeness of resection, how will non-surgical candidates be accounted for?
5) The authors state that the study will redefine the current standard of care for locally advanced gallbladder disease. Since this is a one-center trial being conducted in India, can the authors describe how their patient population and their treatment algorithms compare to those worldwide? Do the authors expect their results to be widely generalizable? 6) Unless I missed them, I did not see the NCT number (although I found it online) or the dates of the planned study in the manuscript (as required by the editors for protocols).
VERSION 1 -AUTHOR RESPONSE
Response This estimation was based on ABC 02 study the median survival for these patients were 11 months The study published from our centre (having a short follow up) where neoadjuvant chemotherapy followed by surgery had MOS of 13 months (Sirohi et al 2015) .
Whereas the MOS of 16.5 months is estimated on the basis of a prospective study (Engineer et al 2016 Ann of surg. Oncol) using neoadjuvant chemoradiation where we observed a MOS of 20 months
In that situation, I recommend the protocol would be better to set randomized phase II study to evaluate R0 resection rate of both arm (selection design) before comparison to upfront surgery. Overall survival should be measured as secondary end point.
Reviewer 3 Due to this slow recruitment the study has been made multicentric and other centers in India (at least 3) where this disease is endemic are in the process of obtaining ethical approval from their respective institutions.
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